Where does Elotuzumab-based combination therapy, specifically EPd, fit in your treatment paradigm for relapsed MM?

Topics: Medical Oncology • Myeloma • NCI-CCC Tumor Board Question • Mayo Clinic • NCI-CCC Myeloma Tumor Board Question

Does sequence matter?

Answer from: Medical Oncologist at Community Practice

The ELOQUENT-2 study evaluated Elotuzumab+Len/Dex vs Len/Dex alone showing improved PFS that was statistically significant and 4-year OS proportion of 50% vs 43% (HR 0.78, 95% CI 0.63-0.96). This required patients essentially be lenalidomide naive in 90% of the study population - something that is v...

Comments

Medical Oncologist at University of Washington, Fred Hutchinson Cancer Research Center
Could not agree more on all fronts. To be honest, ...

Related Questions